Jim Baranski, Executive Director at Lung Cancer Foundation of America, shared a post on LinkedIn:
“I lost my father to small cell lung cancer and understand firsthand how crucial time is for families facing this diagnosis.
The survival gains demonstrated with tarlatamab represent real, measurable hope for patients who have had far too few options.
I appreciate Amgen Oncology’s commitment to advancing treatments in this challenging area and applaud everyone involved in bringing this therapy forward.”
Read the full article: FDA Approves IMDELLTRA for Lung Cancer After a 40% Response Rate
More posts featuring Jim Baranski.